| | | | |
CUSIP No. 73740G106 | | 13D | | Page 4 of 8 Pages |
Item 1. | Security and Issuer. |
This Schedule 13D relates to the shares of common stock (the “Shares”) of Positive Physicians Holdings, Inc., a Pennsylvania corporation (“PPHI”). The address of the principal executive office of PPHI is 100 Berwyn Park, Suite 220, 850 Cassatt Road, Berwyn, Pennsylvania 19312.
Item 2. | Identity and Background. |
(a) This Schedule 13D is filed by (i) Insurance Capital Group, LLC, a Delaware limited liability company (“ICG”) and (ii) Matthew T. Popoli (collectively with ICG, the “Reporting Persons”). Matthew T. Popoli is the controlling owner of ICG and as such may be deemed to beneficially own all of the Shares held directly by ICG. The Reporting Persons are filing this Schedule 13D jointly, as they may be considered a “group” under Section 13(d)(3) of the Securities Exchange Act. However, neither the fact of this filing nor anything contained herein shall be deemed to be an admission by the Reporting Persons that such a group exists. Matthew T. Popoli does not own any of the Shares for his own account and specifically disclaims beneficial ownership of the Shares disclosed in this Schedule 13D.
(b) The principal business address for the Reporting Persons is 767 Fifth Avenue, 16th Floor, New York, New York 10153.
(c) The principal business of ICG is that of a holding company formed for the purpose of acquiring and making investments in insurance businesses across targeted sectors. The principal occupation of Matthew T. Popoli is serving as the Founder and Chief Executive Officer of ICG and as a member on the Board of Directors of PPHI.
(d) During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e) During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction or as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or findings any violation with respect to such laws.
(f) ICG is a Delaware limited liability company. Matthew T. Popoli is a citizen of the United States of America.
Item 3. | Source or Amount of Funds or Other Consideration. |
On June 1, 2018, ICG entered into a Standby Stock Purchase Agreement dated June 1, 2018, as amended on September 21, 2018 (the “Purchase Agreement”), pursuant to which ICG agreed to purchase such number of Shares that would result in the sale of Shares in PPHI’s initial public offering (the “Offering”) in an amount equal to the number of shares at the Minimum of the Valuation Range (as defined in the Purchase Agreement).
In accordance with the FormS-1 filed by PPHI with the SEC on January 22, 2019, and in connection with and following the Offering, ICG acquired 2,277,753 shares of PPHI for total consideration of $22,966,138.25, pursuant to debt financing provided to ICG pursuant to a Credit Agreement dated December 6, 2018 with [***], a copy of which is filed as an exhibit to this Schedule 13D (the “Credit Agreement”), and pursuant to capital contributed by ICG’s members. By virtue of the relationship between ICG and Matthew T. Popoli described in Item 2, Matthew T. Popoli may be deemed to beneficially own all of the Shares held directly by ICG.
Item 4. | Purpose of Transaction. |
The information set forth in Item 3 is incorporated by reference.
The Shares were acquired for investment purposes. The Reporting Persons intend to review the investment in PPHI on an ongoing basis and may take actions (including through its affiliates) with respect to their investment in PPHI, including communicating with the board of directors, members of management or other securityholders of PPHI or other third parties from time to time, taking steps to implement a course of action, including without limitation, engaging advisors, including legal, financial, regulatory, technical and/or industry advisors, to assist in any review, and evaluating strategic alternatives as they may become available.